American Journal of Roentgenology, Vol 166, 683-688, Copyright © 1996 by American Roentgen Ray Society

ARTICLES

Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity

BA Appignani, RA Bhadelia, SC Blacklow, AK Wang, SF Roland and RB Freeman Jr
Department of Radiology, New England Medical Center-Tufts University, Boston, Ma 02111, USA.

OBJECTIVE: The purpose of this study is to describe the neuroimaging (CT and MR imaging) findings in liver transplant patients who develop severe neurologic side effects during immunosuppressive therapy with tacrolimus and to correlate these findings with clinical signs and tacrolimus levels in blood. SUBJECTS AND METHODS: Brain CT and/or MR imaging was performed on six patients who developed neurologic symptoms while receiving tacrolimus in the post-transplant period. All patients were evaluated by the neurology staff, and imaging studies were independently interpreted by three neuroradiologists. Trough tacrolimus levels in blood were measured with the IMX immunoassay and were correlated with neurologic symptoms and imaging findings. RESULTS: Imaging abnormalities were observed in five of six patients during the course of their neurologic illnesses. For each patient, neurologic symptoms began when the tacrolimus level in blood was at a peak, exceeding the therapeutic limit in all but one case. In five patients, neurologic symptoms eventually resolved after the tacrolimus dose was reduced or after the drug was stopped. Multifocal low attenuation of white matter was the predominant finding seen on CT images, and matching hyperintense white matter foci were observed on long-TR MR images. In three patients, clinical recovery was accompanied by reversal of the white matter abnormalities seen on CT and MR images. CONCLUSION: Immunosuppressive therapy with tacrolimus may produce neurologic side effects that are associated with brain CT and MR imaging abnormalities. Resolution of symptoms and reversal of imaging findings occur when the tacrolimus dose is reduced.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				W.S. Bartynski Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical Features AJNR Am. J. Neuroradiol., June 1, 2008; 29(6): 1036 - 1042. [Abstract] [Full Text] [PDF]

				W.S. Bartynski, H.P. Tan, J.F. Boardman, R. Shapiro, and J.W. Marsh Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation AJNR Am. J. Neuroradiol., May 1, 2008; 29(5): 924 - 930. [Abstract] [Full Text] [PDF]

				V. H. Lee, E. F. M. Wijdicks, E. M. Manno, and A. A. Rabinstein Clinical Spectrum of Reversible Posterior Leukoencephalopathy Syndrome Arch Neurol, February 1, 2008; 65(2): 205 - 210. [Abstract] [Full Text] [PDF]

				N. Besenski, Z. Rumboldt, O. Emovon, J. Nicholas, S. Kini, J. Milutinovic, and M. N. Budisavljevic Brain MR Imaging Abnormalities in Kidney Transplant Recipients AJNR Am. J. Neuroradiol., October 1, 2005; 26(9): 2282 - 2289. [Abstract] [Full Text] [PDF]

				K J Ahn, J W Lee, S T Hahn, D W Yang, P S Kim, H J Kim, and C C Kim Diffusion-weighted MRI and ADC mapping in FK506 neurotoxicity Br. J. Radiol., December 1, 2003; 76(912): 916 - 919. [Abstract] [Full Text] [PDF]

				P. J. Oliverio, L. Restrepo, S. A. Mitchell, C. S. Tornatore, and S. R. Frankel Reversible Tacrolimus-induced Neurotoxicity Isolated to the Brain Stem AJNR Am. J. Neuroradiol., July 1, 2000; 21(7): 1251 - 1254. [Abstract] [Full Text] [PDF]

				N. Bargalló, M. Burrel, J. Berenguer, F. Cofan, L. Buñesch, and J. M. Mercader Cortical Laminar Necrosis Caused by Immunosuppressive Therapy and Chemotherapy AJNR Am. J. Neuroradiol., March 1, 2000; 21(3): 479 - 484. [Abstract] [Full Text]

				P. Grimbert, C. Azema, M. Pastural, D. Dhamane, P. Remy, L. Salomon, F. Schortgen, C. Baron, and P. Lang Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2489 - 2491. [Full Text] [PDF]